menu
    • menu

    Company profile for IgGenix

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA. At IgGenix, our mission is to develop first-in-class therapie...
    IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA. At IgGenix, our mission is to develop first-in-class therapies for millions of people whose daily lives are limited by allergies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    IgGenixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    681 Gateway Blvd., Floor 4 South San Francisco, CA 94080
    Telephone
    Telephone
    650-491-9626
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://iggenix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/iggenix-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IgGenix Completes Enrollment for IGNX001 Phase 1 Trial in Peanut
    IgGenix Completes Enrollment for IGNX001 Phase 1 Trial in Peanut

    02 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-02/iggenix-announces-completion-of-enrollment-for-phase-1-clinical-trial-accelerate-peanut-with-ignx0

    PHARMAWEB
    02 Sep 2025
    Share Share
    IgGenix Doses First Patient In Peanut Allergy Trial
    IgGenix Doses First Patient In Peanut Allergy Trial

    16 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iggenix-announces-first-patient-dosed-in-phase-1-clinical-trial-accelerate-peanut-evaluating-ignx001-in-peanut-allergy-302277256.html

    PR NEWSWIRE
    16 Oct 2024
    Share Share
    IgGenix Presents Data On IGNX001 For Peanut Allergy At ASCIA 2024
    IgGenix Presents Data On IGNX001 For Peanut Allergy At ASCIA 2024

    02 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iggenix-presents-data-supporting-clinical-development-of-ignx001-for-peanut-allergy-at-the-2024-ascia-annual-conference-302236196.html

    PR NEWSWIRE
    02 Sep 2024
    Share Share
    IgGenix's IGNX001 Shows Peanut Allergy Potential Ahead Of Clinical Trial
    IgGenix's IGNX001 Shows Peanut Allergy Potential Ahead Of Clinical Trial

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iggenix-demonstrates-potential-of-ignx001-as-a-targeted-therapeutic-for-peanut-allergy-at-the-2024-eaaci-annual-meeting-ahead-of-clinical-trial-launch-302161962.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    IgGenix Announces Patent Granted Covering Allergen-specific Antibodies
    IgGenix Announces Patent Granted Covering Allergen-specific Antibodies

    04 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230404005324/en

    BUSINESSWIRE
    04 Apr 2023
    Share Share
    IgGenix Demonstrated Potential for Single-Cell RNA-Sequencing
    IgGenix Demonstrated Potential for Single-Cell RNA-Sequencing

    02 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230302005126/en

    BUSINESSWIRE
    02 Mar 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search